




## Curriculum Vitae

\* CV must be written in English

Personal Information	
Title (i.e. Pf., Dr., etc.)	Prof.
Name (First Name/ Middle Name /Last Name)	TAE IL / KIM
Degree (i.e. MD, MSc, PhD, etc.)	MD., PhD.
Country	Korea
Affiliation	Yonsei University College of Medicine
E-mail	taeilkim@yuhs.ac
	
Educational Background	
<p>1985 - 1991: Medical Degree, Yonsei University College of Medicine            1993 - 1995: Master course of Medical science, Graduate School, Yonsei University, Seoul, Korea            1995 – 2002: Ph. D. course of Medical science, Graduate School, Yonsei University, Seoul, Korea</p>	
Professional Career	
<p>2012.3.- Present: Professor of Internal Medicine, Division of Gastroenterology, Yonsei University College of Medicine, Korea            2014.5.- 2022.2.: Director of Yonsei Cancer Prevention Center, Yonsei Cancer Center, Severance Hospital            2018.12.- 2019.12: President of Korean Society of Cancer Prevention, Korea            2021.3.- 2023.2.: Director of Division of Gastroenterology, Director of Yonsei Institute of Gastroenterology, Director of Digestive Disease Center, Severance Hospital, Yonsei University College of Medicine, Korea            2023.4.- Present: President of KASID (Korean Association for the Study of Intestinal Diseases)</p>	
Research Field	
<p>Intestinal epithelial biology, Carcinogenesis of colon cancer, Cancer stem cell, Organoid, Intestinal stem cell and regeneration, Microenvironment, Chemoprevention, Familial and hereditary intestinal neoplasia, Prevention and treatment of colorectal neoplasia</p>	
Main Scientific Publications	
<ol style="list-style-type: none"> <li>1. A Comprehensive Understanding of Post-Translational Modification of Sox2 via Acetylation and O-GlcNAcylation in Colorectal Cancer. Seo Y, Kim DK, Kim TI, et al. Cancers (Basel) 2024;16(5).</li> <li>2. Effect of aging on the formation and growth of colonic epithelial organoids by changes in cell cycle arrest through TGF-β-Smad3 signaling. Jo MK, Moon CM, Kim TI, et al. Inflammation and Regeneration 2023;43(1): 35.</li> <li>3. Tumor-Suppressive Effect of Metformin via the Regulation of M2 Macrophages and Myeloid-Derived Suppressor Cells in the Tumor Microenvironment of Colorectal Cancer. Kang J, Kim TI, et al. Cancers 2022;14(12):2881.</li> <li>4. MRI assessment of glutamine uptake correlates with the distribution of glutamine transporters and cancer stem cell markers. Seo Y, Kim TI, et al. Scientific Reports 2022;12(1):5511.</li> <li>5. Application of multigene panel testing in patients with high risk for hereditary colorectal cancer: a descriptive report on genotype-phenotype correlation. Park JS, Kim TI, et al. Diseases of the Colon &amp; Rectum 2022;65(6):793-803.</li> <li>6. Metformin and Niclosamide Synergistically Suppress Wnt and YAP in APC-Mutated Colorectal Cancer. Kang HE, Seo Y, Yun JS, et al. Cancers 2021; 13(14): 3437.</li> </ol>	



7. The Effect of Metformin in Treatment of Adenomas in Patients with Familial Adenomatous Polyposis. Park JJ, Kim BC, Hong SP, et al. *Cancer Prevention Research* 2021;14(5): 563-572.
8. IL-6 and IL-8, secreted by myofibroblasts in the tumor microenvironment, activate HES1 to expand the cancer stem cell population in early colorectal tumor. Kim B, Seo Y, Kwon J, et al. *Molecular Carcinogenesis* 2021;60(3): 188-200.
9. Metformin Suppresses Cancer Stem Cells through AMPK Activation and Inhibition of Protein Prenylation of the Mevalonate Pathway in Colorectal Cancer. Seo Y, Kim J, Park SJ, et al. *Cancers* 2020;12(9): 2554.
10. Effects of metformin on colorectal cancer stem cells depend on alterations in glutamine metabolism. Kim JH, Lee KJ, Seo Y, et al. *Sci Rep* 2018;8:409.